Vaccinex, Inc. (OTC:VCNX) Financings

Vaccinex, Inc.

Financings

RaiseDate
Revenue sharing agreement
Announced: US$60M
Buyers: Pepinemab Development Venture, LP ($60 million funding commitment in exchange for 50% of future economic proceeds from pepinemab neurological indications and 25% from other indications)
Insiders: PDV is an investment entity established by FCMI, an existing Vaccinex investor; Albert Friedberg is Chairman of FCMI and of the Vaccinex Board.
Use of proceeds: Advance development of pepinemab in an enlarged phase 2b clinical trial for Alzheimer's disease
Dec 23, 2025

Read by 6ix AI from the company's releases